Gene expression shifted closer to what researchers observe in cells without the trisomy
In a Japanese laboratory, scientists have crossed a threshold long considered out of reach: using CRISPR-Cas9 gene editing to remove the extra chromosome 21 that defines Down syndrome from human cells grown in a dish. The work, led by researchers at Mie and Fujita Health Universities, does not promise a cure, but it demonstrates that the chromosomal imbalance can be corrected and that gene expression can shift closer to typical patterns — a quiet but consequential expansion of what science believes is possible. For the roughly one in 700 people born each year with trisomy 21, this moment belongs not yet to medicine, but to the long, careful work of understanding.
- For the first time, CRISPR-Cas9 has been used to strip an extra chromosome 21 from human cells, turning a theoretical possibility into a laboratory reality.
- The correction did more than tidy the genome — gene expression patterns in the edited cells shifted measurably closer to those of non-trisomy cells, suggesting the chromosomal imbalance drives biological consequences that can be partially reversed.
- The technique has only been tested in skin and stem cells in a dish; no living organism has been involved, and the effects in brain or nerve tissue — where Down syndrome's impact is most profound — remain entirely unknown.
- Safety is the central obstacle: researchers must confirm that removing a whole chromosome does not introduce unintended cellular damage before any therapeutic path can even be imagined.
- The next phase targets nerve and glial cells, the tissue most relevant to Down syndrome's neurological dimensions, as scientists work to understand whether the correction holds meaning beyond the laboratory dish.
In a Japanese laboratory, scientists have done something that was not possible until now: they removed the extra chromosome 21 responsible for Down syndrome from human cells using CRISPR-Cas9 gene editing. The research, led by Ryotaro Hashizume and colleagues at Mie and Fujita Health Universities and published in PNAS Nexus, worked with skin fibroblasts and pluripotent stem cells, coaxing them back to the standard two copies of chromosome 21 rather than the three that define trisomy 21.
Down syndrome affects approximately one in every 700 births worldwide. That single extra chromosome shapes development across the entire body, influencing physical characteristics, cognitive function, and much more. When the Japanese team removed it from their laboratory cells, gene expression — the way genes switch on and off — shifted noticeably closer to patterns seen in non-trisomy cells. It was a signal that correcting the chromosomal imbalance can restore something of the genome's typical behavior.
The researchers are deliberate about what this work is not. No living person was treated. No organism was involved. The experiments unfolded entirely in dishes, and the road from there to any clinical application is long and uncertain. Safety must be established, and the effects of removing the extra chromosome will need to be studied across many different cell types — what happens in skin may differ profoundly from what happens in the brain.
The next step is testing the technique in nerve and glial cells, the tissue at the heart of Down syndrome's neurological dimensions. Scientists want to know whether the chromosomal correction can influence the biological processes most central to the condition. No cure is promised, and no treatment is near. What has been established is a foundation — proof that the extra chromosome can be removed, that gene expression responds, and that a new avenue of investigation is now open.
In a laboratory in Japan, scientists have successfully removed the extra chromosome that causes Down syndrome from human cells grown in a dish. The achievement, published in the journal PNAS Nexus, represents the first time researchers have used CRISPR-Cas9 gene editing to eliminate the additional copy of chromosome 21 that defines trisomy 21, the genetic condition underlying Down syndrome.
The work was led by Ryotaro Hashizume and his team at Mie University and Fujita Health University. They worked with two types of cells: skin fibroblasts and pluripotent stem cells, which are capable of developing into many different cell types. Using the CRISPR-Cas9 editing tool, the researchers modified these cells so that they retained only the normal two copies of chromosome 21—one inherited from each parent—rather than the three copies present in Down syndrome.
Down syndrome occurs in roughly one of every 700 births worldwide. The condition arises when a person is born with an extra copy of chromosome 21 instead of the standard pair. This single genetic difference affects development and function across the body, influencing everything from physical characteristics to cognitive abilities. For decades, researchers have sought to understand the mechanisms behind this condition and whether genetic intervention might one day offer new treatment possibilities.
When the Japanese team removed the extra chromosome in their laboratory cells, something significant happened: the patterns of gene expression—the way genes turned on and off—shifted closer to what researchers observe in cells without the trisomy. This suggests that correcting the chromosomal imbalance can restore more typical genetic activity. Yet the researchers are careful to emphasize what this work is not. The experiments were conducted entirely in laboratory dishes. No living organisms were involved. No human patients were treated. The technique has never been tested in a living body.
Before any therapeutic application could even be considered, major hurdles remain. Scientists must ensure that the gene-editing process itself is safe and does not introduce unintended damage to cells. They must understand what happens when the extra chromosome is removed in different types of tissue—the effects in skin cells may differ dramatically from effects in brain cells. They must grapple with questions about how the correction might influence the complex biological processes that Down syndrome affects.
The next phase of research will focus on nerve cells and glial cells, the supporting cells of the nervous system. The brain and nervous system are central to many of the characteristics associated with Down syndrome, so testing the technique in these cell types is essential. Researchers want to know whether correcting the chromosomal imbalance in neural tissue can influence the biological processes that the syndrome disrupts.
The scientists acknowledge that clinical application remains distant. Yet they view the work as a meaningful step forward in understanding how Down syndrome develops at the cellular level. By demonstrating that the extra chromosome can be removed and that gene expression can be partially restored, they have opened a new avenue for investigation. The study does not promise a cure or even a near-term treatment. What it does is expand the realm of what researchers believe is possible and provide a foundation for future work that might, eventually, lead somewhere therapeutic.
Citas Notables
The researchers emphasize that the experiments were conducted entirely in laboratory dishes and that no living organisms or human patients were involved— Ryotaro Hashizume and team, Mie University and Fujita Health University
La Conversación del Hearth Otra perspectiva de la historia
What exactly did the scientists remove, and how did they do it?
They used a tool called CRISPR-Cas9 to cut out the extra copy of chromosome 21 from cells grown in the lab. Think of it like a molecular scissors that can find and remove a specific piece of DNA. In Down syndrome, people have three copies of chromosome 21 instead of two, and the team reduced it back to two.
So they fixed it. Can they do this in a person with Down syndrome?
Not yet, and that's the crucial part. This only worked in cells in a dish. No one has tested it in living tissue, let alone in a human being. There are safety questions we don't have answers to yet.
What kind of safety questions?
When you edit genes, you risk making mistakes—cutting the wrong spot, damaging other parts of the DNA. And we don't know if removing the chromosome would have the same effect in every type of cell. The brain is especially complex. What works in skin cells might not work in neurons.
So why is this being called a breakthrough?
Because it proves the concept. For the first time, researchers showed they could actually remove the extra chromosome and restore more normal gene activity. Before this, it was theoretical. Now it's real, even if it's only in a lab.
What happens next?
They'll test the technique on nerve cells and brain cells. If that works, they'll have to figure out how to do it safely in living organisms, then eventually in humans. That's years away, probably decades.
Does this mean Down syndrome could be cured?
It's too early to say. This is one step in a very long process. But it does suggest that genetic intervention might be possible someday.